
Prostate Health Market Share, Size, Trends, Industry Analysis Report, By Disease Indication (Prostate Cancer, Benign Prostate Hyperplasia (BPH), Prostatitis); By Modality (Diagnosis, Treatment); By Treatment (Surgery, Radiation Therapy, Therapeutics); By
Description
Prostate Health Market Share, Size, Trends, Industry Analysis Report, By Disease Indication (Prostate Cancer, Benign Prostate Hyperplasia (BPH), Prostatitis); By Modality (Diagnosis, Treatment); By Treatment (Surgery, Radiation Therapy, Therapeutics); By Region; Segment Forecast, 2022 - 2030
The global prostate health market size is expected t-reach USD 68.0 billion by 2030, according t-a new study by Polaris Market Research. The report “Prostate Health Market Share, Size, Trends, Industry Analysis Report, By Disease Indication (Prostate Cancer, Benign Prostate Hyperplasia (BPH), Prostatitis); By Modality (Diagnosis, Treatment); By Treatment (Surgery, Radiation Therapy, Therapeutics); By Region; Segment Forecast, 2022 – 2030” gives a detailed insight int-current market dynamics and provides analysis on future market growth.
The market’s growth is driven by increasing investments and grants from government organizations in cancer. Various groups are raising cancer awareness and encouraging innovative cancer treatments. This is enhanced by offering funds t-researchers t-further their research.
The various cancer organizations actively supporting cancer through grants include Prostate Cancer Foundation, Cancer Research Institute, Zer-organizations, the American Cancer Society, etc. There is an extensive network of cancer organizations in North America and Europe. The Cancer Research Institute has granted 100 research grants t-studies and initiatives related t-cancer. The organization is investing heavily in new immunotherapy health treatments for cancer. The financial support totals around $26 Billion, with $9 Billion of the CRI Prostate Cancer Initiative funds.
Based on the treatment, the radiation therapy segment accounted for the leading share in the market in 2021. Radiation therapy kills cancer cells by utilizing high-powered light. External beam radiation therapy is a treatment option for cancer. It can als-be administered after surgery t-eliminate any remaining cancer cells if there is a chance that the tumor will spread or return.
Radiation treatment can help slow down the growth of cancer and ease pain such as discomfort if it has migrated t-other parts of the body, such as the bones. Thus, the benefits of radiation therapy for cancer are boosting segmental growth.
Market players include Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Merck & Co., Inc., Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Ferring Pharmaceuticals Inc., End-Pharmaceuticals Inc., Johnson & Johnson, and Siemens Healthcare AG.are some key players operating in the global market.
Polaris Market Research has segmented the prostate health market report based on disease indication, modality, treatment, and region:
Prostate Health, Disease Indication Outlook (Revenue – USD Billion, 2018 – 2030)
The global prostate health market size is expected t-reach USD 68.0 billion by 2030, according t-a new study by Polaris Market Research. The report “Prostate Health Market Share, Size, Trends, Industry Analysis Report, By Disease Indication (Prostate Cancer, Benign Prostate Hyperplasia (BPH), Prostatitis); By Modality (Diagnosis, Treatment); By Treatment (Surgery, Radiation Therapy, Therapeutics); By Region; Segment Forecast, 2022 – 2030” gives a detailed insight int-current market dynamics and provides analysis on future market growth.
The market’s growth is driven by increasing investments and grants from government organizations in cancer. Various groups are raising cancer awareness and encouraging innovative cancer treatments. This is enhanced by offering funds t-researchers t-further their research.
The various cancer organizations actively supporting cancer through grants include Prostate Cancer Foundation, Cancer Research Institute, Zer-organizations, the American Cancer Society, etc. There is an extensive network of cancer organizations in North America and Europe. The Cancer Research Institute has granted 100 research grants t-studies and initiatives related t-cancer. The organization is investing heavily in new immunotherapy health treatments for cancer. The financial support totals around $26 Billion, with $9 Billion of the CRI Prostate Cancer Initiative funds.
Based on the treatment, the radiation therapy segment accounted for the leading share in the market in 2021. Radiation therapy kills cancer cells by utilizing high-powered light. External beam radiation therapy is a treatment option for cancer. It can als-be administered after surgery t-eliminate any remaining cancer cells if there is a chance that the tumor will spread or return.
Radiation treatment can help slow down the growth of cancer and ease pain such as discomfort if it has migrated t-other parts of the body, such as the bones. Thus, the benefits of radiation therapy for cancer are boosting segmental growth.
Market players include Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Merck & Co., Inc., Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Ferring Pharmaceuticals Inc., End-Pharmaceuticals Inc., Johnson & Johnson, and Siemens Healthcare AG.are some key players operating in the global market.
Polaris Market Research has segmented the prostate health market report based on disease indication, modality, treatment, and region:
Prostate Health, Disease Indication Outlook (Revenue – USD Billion, 2018 – 2030)
- Prostate Cancer
- AR Directed Therapies
- Hormone ADT
- Cytotoxic Agents
- PARP Inhibitors
- Others
- Benign Prostate Hyperplasia (BPH)
- Alpha-Blockers
- Alfuzosin
- Doxazosin
- Tamsulosin
- Silodosin
- Other Alpha Blockers
- 5 Alpha Reductase
- Finasteride
- Dutasteride
- Others
- Prostatitis
- Prescription
- Over the counter
- Diagnosis
- Treatment
- Surgery
- Radiation Therapy
- Therapeutics
- Hormone Therapy
- Chemotherapy
- Others
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Netherlands
- Spain
- Austria
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
114 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Modalitys
- 3.2.1. Primary Modalitys
- 3.2.2. Secondary Modalitys
- 4. Global Prostate Health Market Insights
- 4.1. Prostate Health – Industry Snapshot
- 4.2. Prostate Health Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growing prevalence of prostate cancer and BPH
- 4.2.1.2. Emerging Economics
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Low awareness regarding prostate health among men
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Prostate Health Market Industry Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global Prostate Health Market, by Disease Indication
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 5.3. Prostate Cancer
- 5.3.1. Global Prostate Health Market, by Prostate Cancer, by Region, 2018 - 2030 (USD Billion)
- 5.3.2. AR Directed Therapies
- 5.3.2.1. Global Prostate Health Market, by AR Directed Therapies, by Region, 2018 - 2030 (USD Billion)
- 5.3.3. Hormone ADT
- 5.3.3.1. Global Prostate Health Market, by Hormone ADT, by Region, 2018 - 2030 (USD Billion)
- 5.3.4. Cytotoxic Agents
- 5.3.4.1. Global Prostate Health Market, by Cytotoxic Agents, by Region, 2018 - 2030 (USD Billion)
- 5.3.5. PARP Inhibitors
- 5.3.5.1. Global Prostate Health Market, by PARP Inhibitors, by Region, 2018 - 2030 (USD Billion)
- 5.3.6. Others
- 5.3.6.1. Global Prostate Health Market, by Others, by Region, 2018 - 2030 (USD Billion)
- 5.3.7. Mixed Asset
- 5.3.8. Global Prostate Health Market, by Mixed Asset, by Region, 2018 - 2030 (USD Billion)
- 5.4. Benign Prostate Hyperplasia (BPH)
- 5.4.1. Global Prostate Health Market, by Benign Prostate Hyperplasia (BPH), by Region, 2018 - 2030 (USD Billion)
- 5.4.2. Alpha-Blockers
- 5.4.2.1. Global Prostate Health Market, by Alpha-Blockers, by Region, 2018 - 2030 (USD Billion)
- 5.4.2.2. Alfuzosin
- 5.4.2.2.1. Global Prostate Health Market, by Alfuzosin, by Region, 2018 - 2030 (USD Billion)
- 5.4.2.3. Doxazosin
- 5.4.2.3.1. Global Prostate Health Market, by Doxazosin, by Region, 2018 - 2030 (USD Billion)
- 5.4.2.4. Tamsulosin
- 5.4.2.4.1. Global Prostate Health Market, by Tamsulosin, by Region, 2018 - 2030 (USD Billion)
- 5.4.2.5. Silodosin
- 5.4.2.5.1. Global Prostate Health Market, by Silodosin, by Region, 2018 - 2030 (USD Billion)
- 5.4.2.6. Other Alpha Blockers
- 5.4.2.6.1. Global Prostate Health Market, by Other Alpha Blockers, by Region, 2018 - 2030 (USD Billion)
- 5.4.3. 5 Alpha Reductase
- 5.4.3.1. Global Prostate Health Market, by 5 Alpha Reductase, by Region, 2018 - 2030 (USD Billion)
- 5.4.3.2. Finasteride
- 5.4.3.2.1. Global Prostate Health Market, by Finasteride, by Region, 2018 - 2030 (USD Billion)
- 5.4.3.3. Dutasteride
- 5.4.3.3.1. Global Prostate Health Market, by Dutasteride, by Region, 2018 - 2030 (USD Billion)
- 5.4.4. Others
- 5.4.4.1. Global Prostate Health Market, by Others, by Region, 2018 - 2030 (USD Billion)
- 5.5. Prostatitis
- 5.5.1. Global Prostate Health Market, by Prostatitis, by Region, 2018 - 2030 (USD Billion)
- 5.5.2. Prescription
- 5.5.2.1. Global Prostate Health Market, by Prescription, by Region, 2018 - 2030 (USD Billion)
- 5.5.3. Over the counter
- 5.5.3.1. Global Prostate Health Market, by Over the counter, by Region, 2018 - 2030 (USD Billion)
- 6. Global Prostate Health Market, by Modality
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 6.3. Diagnosis
- 6.3.1. Global Prostate Health Market, by Diagnosis, by Region, 2018 - 2030 (USD Billion)
- 6.4. Treatment
- 6.4.1. Global Prostate Health Market, by Treatment, by Region, 2018 - 2030 (USD Billion)
- 7. Global Prostate Health Market, by Treatment
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 7.3. Surgery
- 7.3.1. Global Prostate Health Market, by Surgery, by Region, 2018 - 2030 (USD Billion)
- 7.4. Radiation Therapy
- 7.4.1. Global Prostate Health Market, by Radiation Therapy, by Region, 2018 - 2030 (USD Billion)
- 7.5. Therapeutics
- 7.5.1. Global Prostate Health Market, by Therapeutics, by Region, 2018 - 2030 (USD Billion)
- 7.5.2. Hormone Therapy
- 7.5.2.1. Global Prostate Health Market, by Hormone Therapy, by Region, 2018 - 2030 (USD Billion)
- 7.5.3. Chemotherapy
- 7.5.3.1. Global Prostate Health Market, by Chemotherapy, by Region, 2018 - 2030 (USD Billion)
- 7.5.4. Others
- 7.5.4.1. Global Prostate Health Market, by Others, by Region, 2018 - 2030 (USD Billion)
- 8. Global Prostate Health Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Prostate Health Market Assessment, By Geography, 2018 - 2030 (USD Billion)
- 8.3. Prostate Health Market – North America
- 8.3.1. North America: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.3.2. North America: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.3.3. North America: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.3.4. Prostate Health Market – U.S.
- 8.3.4.1. U.S.: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.3.4.2. U.S.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.3.4.3. U.S.: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.3.5. Prostate Health Market – Canada
- 8.3.5.1. Canada: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.3.5.2. Canada.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.3.5.3. Canada: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.4. Prostate Health Market – Europe
- 8.4.1. Europe: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.4.2. Europe.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.4.3. Europe: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.4.4. Prostate Health Market – UK
- 8.4.4.1. UK: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.4.4.2. UK.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.4.4.3. UK: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.4.5. Prostate Health Market – France
- 8.4.5.1. France: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.4.5.2. France.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.4.5.3. France: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.4.6. Prostate Health Market – Germany
- 8.4.6.1. Germany: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.4.6.2. Germany.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.4.6.3. Germany: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.4.7. Prostate Health Market – Italy
- 8.4.7.1. Italy: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.4.7.2. Italy.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.4.7.3. Italy: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.4.8. Prostate Health Market – Spain
- 8.4.8.1. Spain: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.4.8.2. Spain.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.4.8.3. Spain: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.4.9. Prostate Health Market – Netherlands
- 8.4.9.1. Netherlands: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.4.9.2. Netherlands.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.4.9.3. Netherlands: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.4.10. Prostate Health Market – Austria
- 8.4.10.1. Austria: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.4.10.2. Austria.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.4.10.3. Austria: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.5. Prostate Health Market – Asia Pacific
- 8.5.1. Asia Pacific: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.5.2. Asia Pacific.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.5.3. Asia Pacific: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.5.4. Prostate Health Market – China
- 8.5.4.1. China: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.5.4.2. China.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.5.4.3. China: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.5.5. Prostate Health Market – India
- 8.5.5.1. India: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.5.5.2. India.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.5.5.3. India: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.5.6. Prostate Health Market – Malaysia
- 8.5.6.1. Malaysia: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.5.6.2. Malaysia.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.5.6.3. Malaysia: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.5.7. Prostate Health Market – Japan
- 8.5.7.1. Japan: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.5.7.2. Japan.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.5.7.3. Japan: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.5.8. Prostate Health Market – Indonesia
- 8.5.8.1. Indonesia: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.5.8.2. Indonesia.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.5.8.3. Indonesia: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.5.9. Prostate Health Market – South Korea
- 8.5.9.1. South Korea: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.5.9.2. South Korea.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.5.9.3. South Korea: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.6. Prostate Health Market – Middle East & Africa
- 8.6.1. Middle East & Africa: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.6.2. Middle East & Africa.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.6.3. Middle East & Africa: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.6.4. Prostate Health Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.6.4.3. Saudi Arabia: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.6.5. Prostate Health Market – UAE
- 8.6.5.1. UAE: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.6.5.2. UAE.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.6.5.3. UAE: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.6.6. Prostate Health Market – Israel
- 8.6.6.1. Israel: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.6.6.2. Israel.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.6.6.3. Israel: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.6.7. Prostate Health Market – South Africa
- 8.6.7.1. South Africa: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.6.7.2. South Africa.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.6.7.3. South Africa: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.7. Prostate Health Market – Latin America
- 8.7.1. Latin America: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.7.2. Latin America.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.7.3. Latin America: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.7.4. Prostate Health Market – Mexico
- 8.7.4.1. Mexico: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.7.4.2. Mexico.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.7.4.3. Mexico: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.7.5. Prostate Health Market – Brazil
- 8.7.5.1. Brazil: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.7.5.2. Brazil.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.7.5.3. Brazil: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 8.7.6. Prostate Health Market – Argentina
- 8.7.6.1. Argentina: Prostate Health Market, by Disease Indication, 2018 - 2030 (USD Billion)
- 8.7.6.2. Argentina.: Prostate Health Market, by Treatment, 2018 - 2030 (USD Billion)
- 8.7.6.3. Argentina: Prostate Health Market, by Modality, 2018 - 2030 (USD Billion)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Amgen Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Astellas Pharma Inc.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. AstraZeneca PLC
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Bayer AG
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Bristol-Myers Squibb Co.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Eli Lilly and Company
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Endo Pharmaceuticals Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Ferring Pharmaceuticals Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. GlaxoSmithKline PLC
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Johnson & Johnson
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Merck & Co., Inc.
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Pfizer Inc.
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Siemens Healthcare AG
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.